Acute Cholecystitis Market

Market Overview:

The 7 major acute cholecystitis markets reached a value of USD 3,280.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6,052.1 Million by 2035, exhibiting a growth rate (CAGR) of 5.73% during 2025-2035.

The acute cholecystitis market has been comprehensively analyzed in IMARC's new report titled "Acute Cholecystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Acute cholecystitis is gallbladder inflammation due to cystic duct blockage or inadequate emptying of the gallbladder. Sudden, intense pain in the upper right part of the belly is the main symptom of acute cholecystitis. This pain radiates to the right shoulder. The affected area of the tummy is usually extremely painful, and breathing deeply might exacerbate the pain. Unlike other types of stomach pain, acute cholecystitis discomfort is typically persistent and does not resolve after a few hours. Some individuals may experience additional symptoms, such as a high temperature, nausea, vomiting, feeling unwell, excessive sweating, loss of appetite, yellowing of the skin and the whites of the eyes, etc. The disease is mostly diagnosed using a mix of clinical examination, laboratory testing, and physical examination. The medical practitioner can also conduct imaging tests, such as ultrasound and CT scans, to see the gallbladder and examine for gallstones or other indications of inflammation. In addition, liver function tests may be used to establish the diagnosis and exclude liver or bile duct issues.

The escalating prevalence of gallstones that can block the cystic duct, leading to a buildup of pressure and inflammation within the gallbladder, is primarily driving the acute cholecystitis market. In addition to this, the inflating utilization of intravenous (IV) antibiotics, which act by attacking the infecting bacteria either by killing bacterial cells or inhibiting them from reproducing is also creating a positive outlook for the market. Moreover, the widespread adoption of laparoscopic cholecystectomy owing to its numerous advantages, such as smaller scars, reduced pain, and quicker recovery compared to open cholecystectomy is further bolstering the market growth. This procedure involves removing the gallbladder through small incisions using a camera and specialized tools. Apart from this, the rising application of endoscopic ultrasound-guided gallbladder drainage to drain fluid from the gallbladder in patients with who are high-risk for surgery, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of lipid or polymeric nanoparticles loaded with antibiotics for targeted gallbladder infection control, is expected to drive the acute cholecystitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acute cholecystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute cholecystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute cholecystitis market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute cholecystitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute cholecystitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute cholecystitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the acute cholecystitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the acute cholecystitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the acute cholecystitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of acute cholecystitis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of acute cholecystitis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of acute cholecystitis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with acute cholecystitis across the seven major markets?
• What is the size of the acute cholecystitis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute cholecystitis?
• What will be the growth rate of patients across the seven major markets?

Acute Cholecystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute cholecystitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute cholecystitis market?
• What are the key regulatory events related to the acute cholecystitis market?
• What is the structure of clinical trial landscape by status related to the acute cholecystitis market?
• What is the structure of clinical trial landscape by phase related to the acute cholecystitis market?
• What is the structure of clinical trial landscape by route of administration related to the acute cholecystitis market?